SINTX Technologies Expands Horizons With Strategic Agreements And Innovations
$SINT
SINTX Technologies, Inc. (NASDAQ:SINT), a prominent manufacturer and developer of advanced ceramic materials, has recently announced several significant developments that underscore its commitment to innovation and expansion beyond its traditional biomedical market. The company has entered a Long-Term Agreement (LTA) to supply jet engine components made of silicon nitride, following a rigorous two-year qualification process. This agreement highlights SINTX’s ability to innovate and adapt its manufacturing capabilities to meet the complex demands of the aerospace industry. Dave O’Brien, Executive Vice President and Chief Operating Officer, emphasized the company’s efforts to extend its expertise from medical implants to producing robust jet engine components under an AS9100D certified quality management system. The LTA, which extends to the end of 2026 with an option for renewal, allows SINTX to fulfill all customer requirements for silicon nitride aerospace components, provided it meets specified quality, delivery and purchase order metrics.
This agreement is a testament to the company’s strategic shift towards industrial and aerospace products, with its Maryland facility already producing prototypes for various energy and defense applications. This move signifies SINTX’s broader vision to diversify its product offerings and tap into new markets, leveraging its advanced ceramic technologies. In another significant development, SINTX has been awarded a Phase II grant of $1,972,826 by the National Institutes of Health (NIH) to develop a 3D printed composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This grant represents the fourth NIH award for SINTX since the project’s inception in September 2021. The company aims to combine the clinical efficacy of PEEK with the antibacterial and osteoconductive properties of silicon nitride, using cost-effective 3D printing technologies.
Dr. Ryan Bock, Vice President of Research and Development, highlighted the successful completion of Phase I, which demonstrated the feasibility and reliability of these implants. The Phase II efforts will focus on formal design validation, mechanical testing, biocompatibility assessments and in vivo antimicrobial activity, in collaboration with the University of Pennsylvania School of Veterinary Medicine. This NIH-funded project marks a critical milestone in SINTX’s strategy to introduce a new generation of highly differentiated implants into the spine market. The successful execution of Phase II goals will provide the necessary data to seek FDA regulatory clearance and potentially enable an antimicrobial device claim.
Dr. Sonny Bal, President and CEO, expressed gratitude to the lead university investigators and collaborators for their significant contributions to the project. This initiative underscores SINTX’s commitment to advancing the antibacterial and osseointegration properties of silicon nitride in medical applications. Furthermore, SINTX has announced a collaboration with 3DCERAM Sinto, Inc., a leader in additive manufacturing of advanced ceramics, to develop novel resins and processes for 3D printing ceramic products. This partnership aims to leverage the expertise of both companies to produce unique, high-value resins and 3D printed ceramic components, focusing on the biomedical and investment casting industries.
Dr. Sonny Bal emphasized the potential of silicon nitride-based resins for the biomedical market, predicting that 3D printed silicon nitride devices will play a significant role in the future of medical and technical segments. Michael Halsband, CEO of Sinto America, noted the global interest in these capabilities, particularly in the investment casting industry. The collaboration aims to provide game-changing solutions within these industries, driven by the combined expertise of SINTX and 3DCERAM. This partnership is expected to drive expanded geographical adoption of additive manufactured advanced ceramics, further solidifying the position as a leader in the field.
SINTX Technologies is making significant strides in expanding its market presence and product offerings through strategic agreements and innovative projects. The company’s recent LTA for aerospace components, NIH grant for 3D printed spinal implants and collaboration with 3DCERAM Sinto highlight its commitment to leveraging advanced ceramic technologies in various industries. These developments reflect SINTX’s strategic vision to diversify its capabilities and tap into new markets, positioning itself as a global leader in advanced ceramics. The company continues to innovate and expand, it remains poised to make a substantial impact in the medical, industrial and aerospace sectors.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**
